Medicinal Products

Forxiga

Name Forxiga
Active Substance dapagliflozin propanediol monohydrate
Prescription na recept
Type of prescription ponovljivi recept
Distribution u ljekarni
ATC Code A10BK01
Medicinal product marketed in the Croatia Da
Educational materials
for healthcare professionals
Vodič za zdravstvene radnike, verzija 1
Educational materials
for patients / caregivers
Vodič za bolesnike sa šećernom bolešću tipa 1 i njegovatelje, verzija 1
Kartica s upozorenjima za bolesnika, verzija 1

Note

The medicinal product has been authorised via centralised procedure in all Member States of the European Union based on the European Medicines Agency's expert opinion. Additional information on the medicinal product can be found under the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga

The marketing authorisation has been granted by the European Commission. All marketing authorisations of the European Commission can be found under the following link: http://ec.europa.eu/health/documents/community-register/html/index_en.htm

Direct Healthcare Professional Communication

Name Date Download
Pismo zdravstvenim radnicima s ažuriranim informacijama o riziku od dijabetičke ketoacidoze tijekom liječenja inhibitorima SGLT2 (Invokana*, Vokanamet*, Forxiga, Xigduo, Jardiance, Synjardy*) 14.03.2016 AstraZeneca AB, Boehringer Ingelheim International GmbH i Janssen Cilag International N.V.
Pismo zdravstvenim radnicima o riziku od Fournierove gangrene kod primjene lijekova koji sadrže inhibitore SGLT2 22.01.2019 AstraZeneca d.o.o., Boehringer Ingelheim Zagreb d.o.o.
Back